OncoMatch/Clinical Trials/NCT05675787
Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia
Is NCT05675787 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Medroxyprogesterone acetate + Atorvastatin for atypical endometrial hyperplasia.
Treatment: Medroxyprogesterone acetate + Atorvastatin — To explore the treatment efficacy of medroxyprogesterone acetate plus atorvastatin in patients with atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EEC) for conservative treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Endometrial Cancer
Disease stage
Required: Stage I
Grade: g1
Demographics
Prior therapy
Must have received: progesterone therapy — persistent lesions after one course (12 weeks) OR incomplete remission after 2 courses (24 weeks)
Patients with persistent lesions after one course (12 weeks) of progesterone therapy; Patients who did not achieve complete remission after 2 courses (24 weeks) of progesterone therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05675787 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received progesterone therapy.
What disease stage is eligible?
Stage I is required.
Is there an age limit?
Yes. Patients must be 45 years or younger and at least 17 years old.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages